Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Assessment and Prevention of End-Organ Injury in Sickle Cell Disease
Hematology Disease Topics & Pathways:
sickle cell disease, Adult, Diseases, Hemoglobinopathies, Technology and Procedures, Study Population, Clinically relevant, imaging
Hypothesis: In adult patients with SCD, cerebrovascular reactivity (slope of the vasodilatory response to CO2 (CVR) and the steady-state CVR (amplitude) and speed of the vasodilatory response (tau) to a standardized vasodilatory stimulus CO2), are reduced compared to normal subjects. We also explored for possible associations with clinical characteristics.
Methods: Functional brain imaging performed as part of routine care in adult (≥18) SCD patients (any phenotype) at the University Health Network Comprehensive Sickle Cell Center (Toronto, Canada) between 2017 and 2018 were reviewed. Patients with known cerebral vasculopathy were excluded. CVR was calculated as the change in CBF measured as the blood oxygenation level dependent (BOLD)-MRI signal, in response to a standard vasoactive stimulus of CO2 (delivered by RespirActTM). To calculate the dynamic (tau) and steady-state CVR (amplitude) components of the BOLD signal response, the PET CO2 waveform was convolved with an exponential decay function. The tau corresponding to the best fit between the convolved CO2 and BOLD signal was defined as the speed of vascular response. The slope of the regression between the convolved CO2 and BOLD signal was defined as amplitude.
CVR, amplitude and tau were normalized voxel-wise relative to the mean and standard deviation of the same metric in the corresponding voxels of a previously generated atlas of 42 healthy controls (Z scores). These Z scores were averaged over the vascular territories of the brain for both grey (GM) and white matter (WM). Fisher exact and Pearson correlations were performed to identify possible associations between CVR metrics and SCD comorbid conditions, laboratory parameters, and use of disease-modifying therapy. Associations with univariate P <0.20 were included in the multiple linear regression model. Multi-collinearity was assessed.
Results: Fifteen patients were included in the study. The median age was 27 [IQR22-35]. 5/15 (33.3%) were male. 9/15 (60%) were SS or S/b0 and 5/15 (33.3%) were SC. 4/15 (26.7%) were on transfusion. MRI/MRA uncovered Moya moya in 1 patient. SCI were present in 3/15 (21.4%). Compared to the reference atlas of normal subjects, CVR and amplitude were reduced both in GM and WM (mean Z-score for CVR -0.52 [-1.8 – 0.28] and -0.63 [-2.31 – 0.66]; amplitude -0.26 [-2.61 – 0.66] and -0.28 [-2.70 – 0.60] respectively). Tau was lengthened in GM and WM (mean tau Z-score +0.90 [-0.49 – 3.32] and +0.76 [-0.66 – 2.78] respectively). These abnormal metrics were observed with varying severities in all 3 main vascular territories (Figure). CVR decreased linearly with decreasing hematocrit (Hct) (r=0.59, p=0.03). There was also a trend towards lower CVR in SS or S/b0 patients (t=-1.41, p=0.18, d=0.76) and was highly collinear with Hct. Hematocrit was the only significant independent predictor of CVR metrics on multivariable regression.
Conclusions: All three measures of cerebrovascular health (CVR, amplitude and tau) in SCD patients were abnormal compared to normal controls. Hematocrit appears to be the strongest independent predictor of these measures. The protocol we applied for measuring CVR provides a standardized reproducible vasodilatory stimulus, enabling comparison against a population of healthy individuals for more accurate assessment of CVR in individual subjects. Furthermore, the stimulus protocol produces rapid changes in arterial CO2 levels within one breath that can be used to measure the speed of response of the vasculature representing a novel metric of vascular performance postulated to represent vessel compliance and functional endothelial integrity. These findings show that CVR methodology represents a promising tool to assess disease state, stroke risk, and therapeutic efficacy in sickle cell patients and merits further investigation.
Disclosures: Forté: Canadian Hematology Society: Research Funding; Pfizer - Global Medical Grants: Research Funding. Sobczyk: Thornhill Research Inc.: Current Employment. Duffin: Thornhill Research Inc.: Current Employment. Fisher: Thornhill Research Inc.: Current equity holder in private company. Mikulis: Thornhill Research Inc.: Current equity holder in private company. Kuo: Bioverativ: Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Honoraria; Bluebird Bio: Consultancy; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees; Alexion: Consultancy, Honoraria; Pfizer: Consultancy, Research Funding; Apellis: Consultancy; Celgene: Consultancy.
See more of: Oral and Poster Abstracts